R R

What Is Requip?

Requip is a prescription medication containing ropinirole hydrochloride, a non-ergot dopamine agonist. It is approved to treat Parkinson's disease and moderate to severe primary restless legs syndrome in adults. Requip immediate-release tablets are taken according to different schedules depending on the diagnosis. A separate extended-release ropinirole formulation is used for Parkinson's disease and should not be confused with immediate-release Requip. Ropinirole activates dopamine receptors involved in movement and neurological signaling. It can improve symptoms but does not cure either condition. Treatment requires monitoring for sleepiness, blood pressure changes, and unusual behaviors.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is Requip?

Requip is a prescription medication containing ropinirole hydrochloride, a non-ergot dopamine agonist. It is approved to treat Parkinson's disease and moderate to severe primary restless legs syndrome in adults. Requip immediate-release tablets are taken according to different schedules depending on the diagnosis. A separate extended-release ropinirole formulation is used for Parkinson's disease and should not be confused with immediate-release Requip. Ropinirole activates dopamine receptors involved in movement and neurological signaling. It can improve symptoms but does not cure either condition. Treatment requires monitoring for sleepiness, blood pressure changes, and unusual behaviors.

read more about requip ...

Copy this HTML:

Copy HTML Copied!

How Does Requip Work?

Requip stimulates dopamine receptors in the brain, particularly receptors belonging to the D2 family, including D3 receptors. Dopamine helps regulate movement and other neurological functions. In Parkinson's disease, dopamine-producing nerve cells gradually deteriorate, contributing to tremor, stiffness, and slowed movement. Ropinirole compensates for some of this reduced dopamine signaling. In restless legs syndrome, dopamine receptor stimulation can reduce uncomfortable leg sensations and the urge to move, although the precise therapeutic mechanism is not fully established. Dopamine receptor activation can also affect sleep, blood pressure, perception, and impulse control, contributing to important adverse reactions.

What Conditions Does Requip Treat?

Requip immediate-release tablets are approved for Parkinson's disease and moderate to severe primary restless legs syndrome. Parkinson's disease is a progressive neurological disorder that affects movement and can produce tremor, muscle rigidity, and difficulty initiating movements. Restless legs syndrome causes uncomfortable sensations and an urge to move the legs, typically worsening during rest and in the evening. Requip may be used alone or alongside other Parkinson's treatments when appropriate. It is not approved for every movement disorder or for occasional leg discomfort from other causes. A neurologist evaluates symptoms, other medications, and possible sleep-related complications before prescribing it.

How Should Requip Be Taken?

Requip is taken orally, with or without food. For Parkinson's disease, immediate-release treatment commonly begins at 0.25 mg three times daily and increases gradually according to response, up to a maximum of 24 mg daily. For restless legs syndrome, the recommended starting dose is 0.25 mg once daily, approximately one to three hours before bedtime, with gradual increases to a maximum of 4 mg daily. Patients receiving hemodialysis have lower maximum doses. Treatment should not be stopped abruptly because withdrawal symptoms or worsening neurological symptoms can occur. Significant interruptions in treatment may require restarting at a lower dose and gradual retitration.

What Are the Side Effects and Warnings of Requip?

Common adverse effects include nausea, dizziness, sleepiness, headache, and fatigue. Serious risks include sudden episodes of falling asleep during daily activities, fainting, orthostatic hypotension, hallucinations, and impulse-control disorders such as compulsive gambling or shopping. Requip can also worsen involuntary movements in patients with Parkinson's disease and cause augmentation, or earlier and more severe symptoms, in restless legs syndrome. Abrupt withdrawal may produce anxiety, depression, pain, sweating, and other symptoms. Patients should report sudden sleep episodes, unusual behavior, severe dizziness, or worsening movement symptoms. Driving may be unsafe when sleepiness occurs.

Common Questions About Requip

Is Requip the same as ropinirole?

Yes. Requip is a brand name for immediate-release ropinirole, a dopamine agonist used for Parkinson's disease and moderate to severe primary restless legs syndrome.

Can Requip treat restless legs syndrome?

Yes. Immediate-release Requip is approved for moderate to severe primary restless legs syndrome and is generally taken before bedtime.

Can Requip cause sudden sleep episodes?

Yes. Requip can cause patients to fall asleep during ordinary activities, sometimes without warning. Patients should avoid driving if affected.

Can Requip cause compulsive behaviors?

Yes. Dopamine agonists such as Requip can cause unusual urges involving gambling, spending, eating, or sexual activity. Behavioral changes should be reported to a clinician.

References

Ropinirole. LiverTox. https://www.ncbi.nlm.nih.gov/books/NBK548175/. Date Accessed November 3, 2026.

Ropinirole. MedlinePlus. https://medlineplus.gov/druginfo/meds/a698013.html. Date Accessed November 3, 2026.

Ropinirole. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Ropinirole. Date Accessed November 3, 2026.

Ropinirole. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK554532/. Date Accessed November 3, 2026.

REQUIP and REQUIP XL Patient Information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2deb758c-659e-4e5a-a087-0e9c422f2fe1. Date Accessed November 3, 2026.